一次情報の記録
MentariはInMedとの合併完了と4億9000万ドルの資金調達を発表しました。MT-001第1相試験は進行中で、初期データは2027年半ばに予定されています。MT-002は2027年第1四半期の規制当局への申請に向けた軌道に乗っており、2027年末までに初期データが得られる見込みです。
EX-99.1 2 d183007dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically validated pathways and have potential to address the two-thirds of people who have a suboptimal response to existing anti-CGRP therapies Phase 1 clinical trial for MT-001, a monoclonal antibody targeting PACAP, ongoing with initial data expected mid-2027 MT-002, a bispecific antibody targeting both PACAP and CGRP, is on track for regulatory filing in Q1 2027 with initial data expected by year-end 2027 Company completed two private placement financings with gross proceeds of